5th Oct 2022 13:03
MGC Pharmaceuticals Ltd.
Results of Shareholder's General Meeting
5 October 2022
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') would like to announce the voting results from the Company's General Meeting of shareholders held today, Wednesday, 5 October 2022.
The Company confirms that all motions put to the meeting were voted by poll, with all resolutions carried by a clear majority.
Details of the proxy voting and voting outcomes for all motions put to the meeting are set out in the attached report:
http://www.rns-pdf.londonstockexchange.com/rns/9156B_1-2022-10-5.pdf
--Ends--
Authorised for release by the Company Secretary for further information please contact:
MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 | MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 | UK PR Advisors Tavistock Charles Vivian / Tim Pearson +44 207 920 3150
|
UK Financial and Corporate Advisor Hannam & Partners Rupert Fane / Nilesh Patel +44 7810 056 104 | UK Broker Turner Pope Andy Thacker +44 203 657 0050 |
|
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.
The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.
MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
Related Shares:
MXC.L